|
1
|
Spieker LE, Flammer AJ and Lüscher TF: The
vascular endothelium in hypertension. Handbook Exp Pharmacol.
176:249–283. 2006. View Article : Google Scholar
|
|
2
|
Zhang W, Wang R, Han SF, Bu L, Wang SW, Ma
H and Jia GL: Alpha-linolenic acid attenuates high glucose-induced
apoptosis in cultured human umbilical vein endothelial cells via
PI3K/Akt/eNOS pathway. Nutrition. 23:762–770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fraga-Silva RA, Costa-Fraga FP, Murça TM,
Moraes PL, Martins Lima A, Lautner RQ, Castro CH, Soares CM, Borges
CL, Nadu AP, et al: Angiotensin-converting enzyme 2 activation
improves endothelial function. Hypertension. 61:1233–1238. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun GB, Qin M, Ye JX, Pan RL, Meng XB,
Wang M, Luo Y, Li ZY, Wang HW and Sun XB: Inhibitory effects of
myricitrin on oxidative stress-induced endothelial damage and early
athero-sclerosis in ApoE−/− mice. Toxicol Appl Pharmacol.
271:114–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guan Q, Zhang Y, Yu C, Liu Y, Gao L and
Zhao J: Hydrogen sulfide protects against high-glucose-induced
apoptosis in endothelial cells. J Cardiovasc Pharmacol. 59:188–193.
2012. View Article : Google Scholar
|
|
6
|
Park HS, Cho K, Park YJ and Lee T: Chronic
nicotine exposure attenuates proangiogenic activity on human
umbilical vein endothelial cells. J Cardiovasc Pharmacol.
57:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bellien J, Iacob M, Remy-Jouet I, Lucas D,
Monteil C, Gutierrez L, Vendeville C, Dreano Y, Mercier A, Thuillez
C, et al: Epoxyeicosatrienoic acids contribute with altered nitric
oxide and endothelin-1 pathways to conduit artery endothelial
dysfunction in essential hypertension. Circulation. 125:1266–1275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bellien J, Joannides R, Richard V and
Thuillez C: Modulation of cytochrome-derived epoxyeicosatrienoic
acids pathway: A promising pharmacological approach to prevent
endothelial dysfunction in cardiovascular diseases? Pharmacol Ther.
131:1–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Modena MG, Bonetti L, Coppi F, Bursi F and
Rossi R: Prognostic role of reversible endothelial dysfunction in
hypertensive post-menopausal women. J Am Coll Cardiol. 40:505–510.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Virdis A, Ghiadoni L, Versari D,
Giannarelli C, Salvetti A and Taddei S: Endothelial function
assessment in complicated hypertension. Curr Pharm Des.
14:1761–1770. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wallace SM, Yasmin, McEniery CM,
Mäki-Petäjä KM, Booth AD, Cockcroft JR and Wilkinson IB: Isolated
systolic hypertension is characterized by increased aortic
stiffness and endothelial dysfunction. Hypertension. 50:228–233.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Y, Yabluchanskiy A, Lindsey ML and
Chilton RJ: Is isolated systolic hypertension worse than combined
systolic/diastolic hypertension? J Clin Hypertens (Greenwich).
14:808–809. 2012. View Article : Google Scholar
|
|
13
|
Bellien J, Remy-Jouet I, Iacob M, Blot E,
Mercier A, Lucas D, Dreano Y, Gutierrez L, Donnadieu N, Thuillez C,
et al: Impaired role of epoxyeicosatrienoic acids in the regulation
of basal conduit artery diameter during essential hypertension.
Hypertension. 60:1415–1421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim KY, Shin HK, Choi JM and Hong KW:
Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in
human umbilical vein endothelial cells. J Pharmacol Exp Ther.
300:709–715. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang
S and Du Z; RACTS (Randomized Prospective Antiplatelet Trial of
Cilostazol Versus Ticlopidine in Patients Undergoing Coronary
Stenting) Trial Investigators: RACTS: a prospective randomized
antiplatelet trial of cilostazol versus ticlopidine in patients
undergoing coronary stenting: long-term clinical and angiographic
outcome. J Cardiovasc Pharmacol. 46:162–166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Azuma M, Houchi H, Mizuta M, Kinoshita M,
Teraoka K and Minakuchi K: Inhibitory action of cilostazol, a
phosphodiesterase III inhibitor, on catecholamine secretion from
cultured bovine adrenal chromaffin cells. J Cardiovasc Pharmacol.
41(Suppl 1): S29–S32. 2003.PubMed/NCBI
|
|
17
|
Chao TH, Tseng SY, Li YH, Liu PY, Cho CL,
Shi GY, Wu HL and Chen JH: A novel vasculo-angiogenic effect of
cilostazol mediated by cross-talk between multiple signalling
pathways including the ERK/p38 MAPK signalling transduction
cascade. Clin Sci (Lond). 123:147–159. 2012. View Article : Google Scholar
|
|
18
|
Park SY, Lee JH, Kim CD, Lee WS, Park WS,
Han J, Kwak YG, Kim KY and Hong KW: Cilostazol suppresses
superoxide production and expression of adhesion molecules in human
endothelial cells via mediation of cAMP-dependent protein
kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther.
317:1238–1245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shin HK, Kim YK, Kim KY, Lee JH and Hong
KW: Remnant lipoprotein particles induce apoptosis in endothelial
cells by NAD (P)H oxidase-mediated production of superoxide and
cytokines via lectin-like oxidized low-density lipoprotein
receptor-1 activation: Prevention by cilostazol. Circulation.
109:1022–1028. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lim JH, Woo JS and Shin YW: Cilostazol
protects endothelial cells against lipopolysaccharide-induced
apoptosis through ERK1/2- and P38 MAPK-dependent pathways. Korean J
Intern Med. 24:113–122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McGee MA and Abdel-Rahman AA: Enhanced
vascular PI3K/Akt-NOX signaling underlies the peripheral
NMDAR-mediated pressor response in conscious rats. J Cardiovasc
Pharmacol. 63:395–405. 2014. View Article : Google Scholar :
|
|
23
|
Xu MC, Shi HM, Wang H and Gao XF:
Salidroside protects against hydrogen peroxide-induced injury in
HUVECs via the regulation of REDD1 and mTOR activation. Mol Med
Rep. 8:147–153. 2013.PubMed/NCBI
|
|
24
|
Yang HY, Bian YF, Zhang HP, Gao F, Xiao
CS, Liang B, Li J, Zhang NN and Yang ZM: Angiotensin- (1-7)
treatment ameliorates angiotensin II-induced apoptosis of human
umbilical vein endothelial cells. Clin Exp Pharmacol Physiol.
39:1004–1010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang XS, Ren JH, Lu JP and Fan Y:
Atorvastatin protects against angiotensin II-induced injury and
dysfunction in human umbilical vein endothelial cells through
bradykinin 2 receptors. J Cardiovasc Pharmacol. 56:171–176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Q, Zhang M, Ding Y, Wang Q, Zhang W,
Song P and Zou MH: Activation of NAD (P)H oxidase by
tryptophan-derived 3-hydroxykynurenine accelerates endothelial
apoptosis and dysfunction in vivo. Circ Res. 114:480–492. 2014.
View Article : Google Scholar :
|
|
27
|
Urso C and Caimi G: Oxidative stress and
endothelial dysfunction. Minerva Med. 102:59–77. 2011.In Italian.
PubMed/NCBI
|
|
28
|
Xu Y, Ruan S, Xie H and Lin J: Role of
LOX-1 in Ang II-induced oxidative functional damage in renal
tubular epithelial cells. Int J Mol Med. 26:679–690. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YH, Marquez AP, Mungunsukh O and Day
RM: Hepatocyte growth factor inhibits apoptosis by the profibrotic
factor angiotensin II via extracellular signal-regulated kinase 1/2
in endothelial cells and tissue explants. Mol Biol Cell.
21:4240–4250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Riwanto M, Rohrer L, Roschitzki B, Besler
C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von
Eckardstein A, et al: Altered activation of endothelial anti- and
proapoptotic pathways by high-density lipoprotein from patients
with coronary artery disease: Role of high-density
lipoprotein-proteome remodeling. Circulation. 127:891–904. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. National Academy
Press; Washington, DC: 1996
|
|
32
|
Cassis LA, Marshall DE, Fettinger MJ,
Rosenbluth B and Lodder RA: Mechanisms contributing to angiotensin
II regu-lation of body weight. Am J Physiol. 274:E867–E876.
1998.PubMed/NCBI
|
|
33
|
Su F, Shi M, Yan Z, Ou D, Li J, Lu Z and
Zheng Q: Simvastatin modulates remodeling of Kv4.3 expression in
rat hypertrophied cardiomyocytes. Int J Biol Sci. 8:236–248. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu
C, Viollet B, Yan D and Zou MH: AMPKalpha2 deletion causes aberrant
expression and activation of NAD (P)H oxidase and consequent
endothelial dysfunction in vivo: Role of 26S proteasomes. Circ Res.
106:1117–1128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giachini FR, Osmond DA, Zhang S, Carneiro
FS, Lima VV, Inscho EW, Webb RC and Tostes RC: Clopidogrel,
independent of vascular P2Y12 receptor, improves the arterial
function in small mesenteric arteries from Ang II-hypertensive
rats. Clin Sci (Lond). 118(7): 463–71. 2010. View Article : Google Scholar
|
|
36
|
Sanchez M, Lodi F, Vera R, Villar IC,
Cogolludo A, Jimenez R, Moreno L, Romero M, Tamargo J,
Perez-Vizcaino F, et al: Quercetin and isorhamnetin prevent
endothelial dysfunction, superoxide production, and overexpression
of p47phox induced by angiotensin II in rat aorta. J Nutr.
137:910–915. 2007.PubMed/NCBI
|
|
37
|
Li R, Wang WQ, Zhang H, Yang X, Fan Q,
Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F, et al:
Adiponectin improves endothelial function in hyperlipidemic rats by
reducing oxidative/nitrative stress and differential regulation of
eNOS/iNOS activity. Am J Physiol Endocrinol Metab. 293:E1703–E1708.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gonzalez AA, Green T, Luffman C, Bourgeois
CR, Navar LG and Prieto MC: Renal medullary cyclooxygenase-2 and
(pro)renin receptor expression during angiotensin II-dependent
hypertension. Am J Physiol Renal Physiol. 307(8): F962–70. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pezeshki Z, Eshraghi-Jazi F and
Nematbakhsh M: Vascular response to graded angiotensin II infusion
in offspring subjected to high-salt drinking water during
pregnancy: The effect of blood pressure, heart rate, urine output,
endothelial permeability, and gender. Int J Vasc Med.
2014:8765272014.PubMed/NCBI
|
|
40
|
Xu Z, Lu G and Wu F: Simvastatin
suppresses homocysteine-induced apoptosis in endothelial cells:
Roles of caspase-3, cIAP-1 and cIAP-2. Hypertens Res. 32:375–380.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dimmeler S and Zeiher AM: Endothelial cell
apoptosis in angiogenesis and vessel regression. Circ Res.
87:434–439. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vergeade A, Mulder P, Vendeville C,
Ventura-Clapier R, Thuillez C and Monteil C: Xanthine oxidase
contributes to mitochondrial ROS generation in an experimental
model of cocaine-induced diastolic dysfunction. J Cardiovasc
Pharmacol. 60:538–543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dharmashankar K and Widlansky ME: Vascular
endothelial function and hypertension: Insights and directions.
Curr Hypertens Rep. 12:448–455. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schäfer SC, Pellegrin M, Wyss C, Aubert
JF, Nussberger J, Hayoz D, Lehr HA and Mazzolai L: Intravital
microscopy reveals endothelial dysfunction in resistance arterioles
in Angiotensin II-induced hypertension. Hypertens Res. 35:855–861.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Daugherty A, Manning MW and Cassis LA:
Angiotensin II promotes atherosclerotic lesions and aneurysms in
apolipoprotein E-deficient mice. J Clin Invest. 105:1605–1612.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Caplan BA and Schwartz CJ: Increased
endothelial cell turnover in areas of in vivo Evans Blue uptake in
the pig aorta. Atherosclerosis. 17:401–417. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu T, Shen D, Xing S, Chen J, Yu Z, Wang
J, Wu B, Chi H, Zhao H, Liang Z, et al: Attenuation of exogenous
angiotensin II stress-induced damage and apoptosis in human
vascular endothelial cells via microRNA-155 expression. Int J Mol
Med. 31:188–196. 2013.
|
|
48
|
Marampon F, Gravina GL, Scarsella L,
Festuccia C, Lovat F, Ciccarelli C, Zani BM, Polidoro L, Grassi D,
Desideri G, et al: Angiotensin-converting-enzyme inhibition
counteracts angiotensin II-mediated endothelial cell dysfunction by
modulating the p38/SirT1 axis. J Hypertens. 31:1972–1983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nako H, Kataoka K, Koibuchi N, Dong YF,
Toyama K, Yamamoto E, Yasuda O, Ichijo H, Ogawa H and Kim-Mitsuyama
S: Novel mechanism of angiotensin II-induced cardiac injury in
hypertensive rats: The critical role of ASK1 and VEGF. Hypertens
Res. 35:194–200. 2012. View Article : Google Scholar
|
|
50
|
Chen J, Chen W, Zhu M, Zhu Y, Yin H and
Tan Z: Propofol attenuates angiotensin II-induced apoptosis in
human coronary artery endothelial cells. Br J Anaesth. 107:525–532.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kröller-Schön S, Jansen T, Schüler A,
Oelze M, Wenzel P, Hausding M, Kerahrodi JG, Beisele M, Lackner KJ,
Daiber A, et al: Peroxisome proliferator-activated receptor γ,
coactivator 1α deletion induces angiotensin II-associated vascular
dysfunction by increasing mitochondrial oxidative stress and
vascular inflammation. Arterioscler Thromb Vasc Biol. 33:1928–1935.
2013. View Article : Google Scholar
|
|
52
|
Gealekman O, Abassi Z, Rubinstein I,
Winaver J and Binah O: Role of myocardial inducible nitric oxide
synthase in contractile dysfunction and beta-adrenergic
hyporesponsiveness in rats with experimental volume-overload heart
failure. Circulation. 105:236–243. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen F, Wu JL, Fu GS, Mou Y and Hu SJ:
Chronic treatment with qiliqiangxin ameliorates aortic endothelial
cell dysfunction in diabetic rats. J Cardiovasc Pharmacol Ther.
20:230–40. 2015. View Article : Google Scholar
|
|
54
|
Kossmann S, Hu H, Steven S, Schönfelder T,
Fraccarollo D, Mikhed Y, Brähler M, Knorr M, Brandt M, Karbach SH,
et al: Inflammatory monocytes determine endothelial nitric-oxide
synthase uncoupling and nitro-oxidative stress induced by
angiotensin II. J Biol Chem. 289:27540–27550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Napoli C, Paolisso G, Casamassimi A,
Al-Omran M, Barbieri M, Sommese L, Infante T and Ignarro LJ:
Effects of nitric oxide on cell proliferation: Novel insights. J Am
Coll Cardiol. 62:89–95. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Laskin DL and Pendino KJ: Macrophages and
inflammatory mediators in tissue injury. Annu Rev Pharmacol
Toxicol. 35:655–677. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang W, Fu F, Tie R, Liang X, Tian F,
Xing W, Li J, Ji L, Xing J, Sun X, et al: Alpha-linolenic acid
intake prevents endothelial dysfunction in high-fat diet-fed
streptozotocin rats and underlying mechanisms. Vasa. 42:421–428.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yu J, Li M, Qu Z, Yan D, Li D and Ruan Q:
SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal
cells toward areas of heart myocardial infarction through
activation of PI3K/Akt. J Cardiovasc Pharmacol. 55:496–505.
2010.PubMed/NCBI
|
|
59
|
Zheng H, Fu G, Dai T and Huang H:
Migration of endothelial progenitor cells mediated by stromal
cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal
transduction pathway. J Cardiovasc Pharmacol. 50:274–280. 2007.
View Article : Google Scholar : PubMed/NCBI
|
